Objective: To observe the effects of valsartan combined with atorvastatin on cardiac function, myocardial enzymes and thyroxine levels in patients with chronic heart failure (CHF). Methods: 90 cases of CHF cases were divided into observation group and control group according to the order of single and double number, 45 cases each. In the control group, atorvastatin was given on the basis of conventional therapy, and the observation group was given valsartan on the basis of the control group. After 6 months, the differences of cardiac function indexes (LVEF, LVEDD, LVESD, E/A), myocardial enzymes (LDH, AST, CK, CKMB) and thyroxine (TT3, TT4, FT3, FT4, TSH) in the two groups were observed. Results: After treatment, LVEF and E/A in both groups increased significantly (P<0.05), while LVEDD and LVESD decreased significantly (P<0.05), and LVEF (49.05±5.37)% and E/A (1.13±0.19) are higher than the control group ,while LVEDD (51.55±5.26) mm and LVESD (38.87±3.61) mm are lower than the control group, the difference was statistically significant (P<0.05); After treatment, two groups of LDH, AST, CK, CK-MB were significantly decreased (P<0.05), LDH, AST, CK and CK-MB in the observation group were (165.06±29.45) IU/L, (31.51±13.33) IU/L, (96.45±29.58) mmol/L and (19.53±8.75) mmol/L respectively, lower than the control group, the differences were statistically significant (P<0.05); After treatment, two groups of TT3 and FT3 increased significantly (P<0.05) while TT4, FT4 and TSH levels had no significant changes (P>0.05), the observation group TT3 and FT3 were respectively (1.37±0.33) mol/L and (2.61±0.69) pmol/L , higher than the control group, the difference was statistically significant (P<0.05). Conclusion: valsartan combined with atorvastatin in the treatment of CHF, can improve cardiac function and myocardial protection effect, and can effectively promote the recovery of thyroid hormone levels, better than the single use of atorvastatin.